J. Alba Dominguez's scientific contributions
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (2)
Background: Overexpression of HER2/neu gene or protein is found in 20% to 30% of breast carcinomas and is predictive of response to treatment by trastuzumab. Methods such as FISH or CISH determine gene amplification status, however, amplified genes may or may not be all transcribed at equivalent levels. Recently, a new c-erbB-2 probe for rapid in s...
Development of a unique in situ assay detecting the Her2 mRNA in combination with the Her2 protein in FFPE breast cancer specimens.
Citations
... It uses a peroxidase enzyme-labeled probe for chromogenic detection using diaminobenzidine [55]. Meanwhile, some new methods (HER2-V2, MLPA, NGS, RISH) are also in clinical trials and have yet to be approved by FDA [57][58][59][60][61]. They showed good superiority: more accurate patient stratification, fast and inexpensive, need a tiny amount of DNA, and identify mutations in HER2 segments [59][60][61][62][63]. ...